Predictor for Re-treatment of Overactive Bladder Syndrome After Discontinuation of Mirabegron Treatment for Female Overactive Bladder Syndrome
Overview
- Phase
- Not Applicable
- Intervention
- Mirabegron 25mg
- Conditions
- Recurrence of Overactive Bladder Syndrome
- Sponsor
- National Taiwan University Hospital
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Recurrent OAB
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
Recurrence of female overactive bladder syndrome (OAB) is not uncommon. It is important to decrease the recurrence of female OAB. However, factors predicting recurrence of female OAB, especially for those women who need retreatment is undetermined. Thus, the aim of this study was to elucidate factors predicting retreatment of female OAB.
Detailed Description
The medical records, including pad testing, urodynamic studies, lower urinary tract symptoms related questionnaires and bladder diaries of all consecutive women with OAB, who visited urogynecologic clinics in a tertiary referral center, were reviewed. Persistence interval was defined from the date of prescription of mirabegron to the date of discontinuation of mirabegron treatment. Statistical analysis was performed with Kaplan-Meier estimator. Multivariable Cox proportional-hazard model with all variables with p \< 0.25 in the univariate analysis was performed to predict OAB retreatment probability.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women with overactive bladder syndrome
- •Women complete urodynamic study and bladder diary
Exclusion Criteria
- •Pregnant women
- •Incomplete data
- •Loss of follow-up
- •Acute or chronic urinary tract infection
Arms & Interventions
Women received Mirabegron
Women with overactive bladder syndrome received Mirabegron
Intervention: Mirabegron 25mg
Outcomes
Primary Outcomes
Recurrent OAB
Time Frame: January 2015 to July 2019
Recurrent OAB with needs to retreatment